“For three decades, the 340B drug pricing program has helped hospitals that serve high numbers of low-income patients offer and expand a range of important programs and services that advance health within their communities,” writes AHA President and CEO Rick Pollack in the Congress Blog at The Hill. READ MORE

Related News Articles

Headline
AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the…
Headline
AHA March 12 released a new report from Healthsperien on discounts to 340B hospitals through the 340B Drug Pricing Program relative to drug company revenues…
Headline
The U.S. Court of Appeals for the 8th Circuit March 12 upheld Arkansas’ 340B Drug Pricing Nondiscrimination Act against a constitutional challenge brought by…
Headline
AHA Feb. 29 filed a friend-of-the-court brief in support of a Louisiana law that prohibits drug companies from denying Louisiana hospitals the same 340B…
Blog
A new study published in the New England Journal of Medicine demonstrates a stunning lack of understanding of the 340B drug pricing program and the…
Headline
A bipartisan group of senators Feb. 2 released for stakeholder feedback a discussion draft of legislation to clarify in statute Congress’ intent for the 340B…